Product Description: PKT-276, an analogue of PKT-185, is an oral bioavailable and selective inhibitor of nuclear output (SINE). PKT-276 is also a CRM1 antagonist that irreversibly binds to and blocks the function of CRM1[1].
Applications: Cancer-programmed cell death
Formula: C16H10F8N4O
References: [1]Ranganathan P, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood. 2012 Aug 30;120(9):1765-73./[2]Zhang K, et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013 Jan;41(1):67-78.e4./[3]Schmidt J, et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013 Dec;27(12):2357-65.
CAS Number: 1421919-75-6
Molecular Weight: 426.26
Compound Purity: 99.75
Research Area: Cancer
Solubility: DMSO : 20 mg/mL (ultrasonic)
Target: CRM1
Deutsch
English
